Evidence map›Paper›PMID 30646939›Full record

ReviewClinical epigenetics2019

Epigenetic therapy for ovarian cancer: promise and progress.

Sara Moufarrij, Monica Dandapani, Elisa Arthofer, Stephanie Gomez, Aneil Srivastava, Micael Lopez-Acevedo, Alejandro Villagra, Katherine B Chiappinelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.Apoptosis : an international journal on programmed cell death · 2025
    Review
  18. Article
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara MoufarrijDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA.
Monica DandapaniDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA.
Elisa ArthoferDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA.
Stephanie GomezDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA.
Aneil SrivastavaDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA.
Micael Lopez-AcevedoDepartment of Obstetrics & Gynecology, The George Washington University, Washington, D.C., 20052, USA.
Alejandro VillagraDepartment of Biochemistry & Molecular Medicine, The George Washington University, Washington, D.C., 20052, USA.
Katherine B ChiappinelliDepartment of Microbiology, Immunology, & Tropical Medicine, The George Washington University, Washington, D.C., 20052, USA. kchiapp1@gwu.edu.

Funding

Epigenetic activation of the interferon response to sensitize cancers to immune therapyR00CA204592 · NCI · GEORGE WASHINGTON UNIVERSITY · PI CHIAPPINELLI, KATHERINE B · 2017 to 2019
$747k
NCI NIH HHS R00 CA204592
6 · The paper itself

Abstract

Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most ovarian cancers are epithelial in origin and treatment prioritizes surgery and cytoreduction followed by cytotoxic platinum and taxane chemotherapy. While most tumors will initially respond to this treatment, recurrence is likely to occur within a median of 16 months for patients who present with advanced stage disease. New treatment options separate from traditional chemotherapy that take advantage of advances in understanding of the pathophysiology of ovarian cancer are needed to improve outcomes. Recent work has shown that mutations in genes encoding epigenetic regulators are mutated in ovarian cancer, driving tumorigenesis and resistance to treatment. Several of these epigenetic modifiers have emerged as promising drug targets for ovarian cancer therapy. In this article, we delineate epigenetic abnormalities in ovarian cancer, discuss key scientific advances using epigenetic therapies in preclinical ovarian cancer models, and review ongoing clinical trials utilizing epigenetic therapies in ovarian cancer.

Indexed as

Antineoplastic AgentsClinical Trials as TopicDrug Resistance, NeoplasmEpigenesis, GeneticFemaleHumansMolecular Targeted TherapyMutationNeoplasm StagingOvarian NeoplasmsAntineoplastic AgentsDNA methylationDNMT inhibitorsEpigeneticsHDAC inhibitorsHistone modificationsOvarian cancer

Identifiers

PMID30646939
PMCPMC6334391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.